OUR VISION
We are building a leading, next generation precision medicine company utilizing the power of ultrasound to enable targeted drug delivery in oncology
EXACT Therapeutics announces first patient dosed in Phase 2 trial in patients with locally advanced pancreatic cancer
KEY FOCUS AREA
Focus on Oncology
We are united in the mission:
ACT® against pancreatic cancer
Latest company news:
-
Core patent granted in the USA
On July 8, EXACT was granted a core patent that covers the treatment of patients with a pharmaceutical using EXACT’s proprietary agent PS101 and Acoustic Cluster Therapy (ACT®)
-
First patient dosed in Phase 2 trial
EXACT announces first patient dosed in its ENACT trial on June 24, 2025
-
Minutes from EXACT Therapeutics AGM, June 13
-
AGM June 13, 2025
Notice and registration forms for the Annual General Meeting on June 13, 2025.
Our pipeline
Our technology
The Key differentiation of ACT® is:
ACT® has a biomechanical mode of action to increase the uptake of co-administered drugs from blood vessels into the surrounding (cancer) tissue, without damaging the cells within the capillary walls; unlike sonoporation, ACT® does not create holes in the epithelial cell membranes of the capillary wall.
With ACT®, the drug can reach 100 microns which is 10 layers of cells away from capillary with an ongoing pump effect that lasts for minutes.
Reproducible and signifcant uptake through targeted delivery into tumours and across the blood brain barrier (BBB).
A very strong toxicology package:
including most recently, in relation to BBB opening where no extravasation of red blood cells was observed throughout the ACT® procedure in a preclinical rodent model.
Uses a bespoke dual frequency transducer with a standard ultrasound scanner to activate and enhance the clusters at the target tumour site. Compatible with existing ultrasound systems widely available in clinics/hospitals worldwide.
No drug reformulation required.
ACT® relies on ultrasound settings well within safe and approved ranges.
State of the art navigation system in development to ensure ACT® is delivered accurately at a targeted site